These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 30701099)
1. The breast cancer patient in the cardioncology unit. Cardinale D; Caruso V; Cipolla CM J Thorac Dis; 2018 Dec; 10(Suppl 35):S4306-S4322. PubMed ID: 30701099 [TBL] [Abstract][Full Text] [Related]
2. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087 [TBL] [Abstract][Full Text] [Related]
3. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427 [TBL] [Abstract][Full Text] [Related]
4. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss. Cardinale D; Biasillo G; Cipolla CM Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238 [TBL] [Abstract][Full Text] [Related]
6. Role of biomarkers in cardioncology. Cardinale D; Salvatici M; Sandri MT Clin Chem Lab Med; 2011 Sep; 49(12):1937-48. PubMed ID: 21892906 [TBL] [Abstract][Full Text] [Related]
7. Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers. Chianca M; Fabiani I; Del Franco A; Grigoratos C; Aimo A; Panichella G; Giannoni A; Castiglione V; Gentile F; Passino C; Cipolla CM; Cardinale DM; Emdin M Eur J Prev Cardiol; 2022 Dec; 29(17):2163-2172. PubMed ID: 35938306 [TBL] [Abstract][Full Text] [Related]
8. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741 [TBL] [Abstract][Full Text] [Related]
9. Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors. Fabian C Adv Exp Med Biol; 2015; 862():213-30. PubMed ID: 26059938 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165 [TBL] [Abstract][Full Text] [Related]
13. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836 [TBL] [Abstract][Full Text] [Related]
14. Cardioncology: state of the heart. Todaro MC; Oreto L; Qamar R; Paterick TE; Carerj S; Khandheria BK Int J Cardiol; 2013 Sep; 168(2):680-7. PubMed ID: 23639459 [TBL] [Abstract][Full Text] [Related]
15. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Mecinaj A; Gulati G; Heck SL; Holte E; Fagerland MW; Larsen AI; Blix ES; Geisler J; Wethal T; Omland T Cardiooncology; 2021 Sep; 7(1):33. PubMed ID: 34579775 [TBL] [Abstract][Full Text] [Related]
17. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Murtagh G; Lyons T; O'Connell E; Ballot J; Geraghty L; Fennelly D; Gullo G; Ledwidge M; Crown J; Gallagher J; Watson C; McDonald KM; Walshe JM Breast Cancer Res Treat; 2016 Apr; 156(3):501-506. PubMed ID: 27060913 [TBL] [Abstract][Full Text] [Related]
18. Cancer treatment-related cardiac dysfunction in breast cancer survivors: A retrospective descriptive study using electronic health records from a Korean tertiary hospital. Lim A; Jang H; Jeon M; Fadol AP; Kim S Eur J Oncol Nurs; 2022 Aug; 59():102163. PubMed ID: 35716453 [TBL] [Abstract][Full Text] [Related]
19. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285 [TBL] [Abstract][Full Text] [Related]
20. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Tajiri K; Aonuma K; Sekine I Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]